Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.46)
# 4,294
Out of 4,634 analysts
216
Total ratings
45.3%
Success rate
-3.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Reiterated: Buy | $9 | $2.86 | +214.69% | 20 | Aug 5, 2026 | |
| CING Cingulate | Maintained: Buy | $10 | $5.25 | +90.48% | 25 | Jul 31, 2026 | |
| PMN ProMIS Neurosciences | Reiterated: Buy | $19 → $30 | $14.72 | +103.80% | 2 | Jul 29, 2026 | |
| PYPD PolyPid | Maintained: Buy | $9 | $4.77 | +88.68% | 20 | Jul 29, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | $38 → $7 | $3.85 | +81.82% | 17 | Jul 28, 2026 | |
| ANVS Annovis Bio | Initiated Coverage: Buy | $8 | $1.89 | +323.28% | 1 | Jul 9, 2026 | |
| COYA Coya Therapeutics | Maintained: Buy | $12 | $4.62 | +159.63% | 2 | Jul 6, 2026 | |
| GANX Gain Therapeutics | Maintained: Buy | $8 | $1.77 | +351.98% | 28 | Jul 1, 2026 | |
| NRSN NeuroSense Therapeutics | Maintained: Buy | $3 | $0.4842 | +519.58% | 6 | Jun 10, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $10 | $6.95 | +43.88% | 21 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $37 | $45.85 | -19.30% | 5 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $3 | $0.7363 | +307.44% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $26 → $19 | $14.10 | +34.75% | 5 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 → $7 | $2.62 | +167.18% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.43 | +132.56% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.4305 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7901 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.33 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $46.20 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $29.54 | n/a | 6 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.3 | $35.00 | n/a | 5 | Sep 19, 2023 |
CervoMed
Aug 5, 2026
Reiterated: Buy
Price Target: $9
Current: $2.86
Upside: +214.69%
Cingulate
Jul 31, 2026
Maintained: Buy
Price Target: $10
Current: $5.25
Upside: +90.48%
ProMIS Neurosciences
Jul 29, 2026
Reiterated: Buy
Price Target: $19 → $30
Current: $14.72
Upside: +103.80%
PolyPid
Jul 29, 2026
Maintained: Buy
Price Target: $9
Current: $4.77
Upside: +88.68%
Capricor Therapeutics
Jul 28, 2026
Downgraded: Hold
Price Target: $38 → $7
Current: $3.85
Upside: +81.82%
Annovis Bio
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.89
Upside: +323.28%
Coya Therapeutics
Jul 6, 2026
Maintained: Buy
Price Target: $12
Current: $4.62
Upside: +159.63%
Gain Therapeutics
Jul 1, 2026
Maintained: Buy
Price Target: $8
Current: $1.77
Upside: +351.98%
NeuroSense Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $3
Current: $0.4842
Upside: +519.58%
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $10
Current: $6.95
Upside: +43.88%
May 18, 2026
Rated: Buy
Price Target: $31 → $37
Current: $45.85
Upside: -19.30%
May 15, 2026
Reiterated: Buy
Price Target: $2 → $3
Current: $0.7363
Upside: +307.44%
May 14, 2026
Rated: Buy
Price Target: $26 → $19
Current: $14.10
Upside: +34.75%
May 14, 2026
Rated: Buy
Price Target: $5 → $7
Current: $2.62
Upside: +167.18%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.43
Upside: +132.56%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.4305
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.7901
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $15.33
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $46.20
Upside: n/a
Oct 24, 2023
Maintained: Hold
Price Target: n/a
Current: $29.54
Upside: n/a
Sep 19, 2023
Reiterated: Hold
Price Target: $0.3
Current: $35.00
Upside: n/a